Clinical trial
Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated…
NCT00179725 · Celgene Corporation, Industry · Terminated
Key facts
| NCT number | NCT00179725 |
|---|---|
| Title | Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma |
| Official title | Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid®) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma |
| Lead sponsor | Celgene Corporation, Industry |
| Collaborators | Prologue Research International Industry |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer |
| Intervention type | Drug |
| Interventions | CC-5013, liposomal doxorubicin |
| Enrollment | 60 |
| Start date | Nov 1, 2005 |
| Completion | Jun 1, 2007 |
| First posted | Sep 16, 2005 |
| Last update posted | Apr 12, 2006 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: